Inclusion criteria: <br>- Male or female, 18 years or older.<br>- Histologically or cytologically confirmed diagnosis of NSCLC that is Stage IIIb, IV or recurrent.<br>- mGPS of 1 or 2 as defined below:<br>- mGPS of 1: C-reactive protein (CRP) > 10 mg/L and albumin = 35 g/L<br>- mGPS of 2: CRP > 10 mg/L and albumin < 35 g/L.<br>- Radiographically measurable or evaluable disease.<br>- Measurable lesions may be in the field of prior radiation; however, there must be at least a 4-week period between the last radiation treatment and demonstration of interval progression of the lesion compared with the baseline scan documenting disease status for the lesion to be considered measurable.<br>- Received only 1 prior systemic chemotherapy regimen for Stage IIIb, IV, or recurrent disease (not including neoadjuvant and/or adjuvant therapy except as noted below).<br>- Prior systemic regimens must include a platinum based therapy. Investigational agents used in combination with standard platinum therapies are allowed.<br>- Tumors with driver mutations (EGFR mutation positive or ALK fusion oncogene positive) are allowed provided they also had prior treatment with a tyrosine kinase inhibitor (TKI).<br>- Maintenance therapy after first-line chemotherapy is allowed provided that the maintenance therapy did not include docetaxel or other taxane.<br>- Subjects who completed a platinum-containing regimen as adjuvant, neoadjuvant, or part of a course of chemoradiation therapy within the 6 months before screening are allowed.<br>- Prior treatment of advanced or metastatic disease with immune targeted therapy is allowed. <br> = 3 weeks or 5 half-lives (whichever is longer) have elapsed from the completion of previous systemic therapy regimen (including maintenance therapy or immunotherapy) prior to the initiation of therapy and subjects must have recovered or be at a new stable baseline from any related toxicities prior to dosing.<br>- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 40<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 60<br>